Absci Corporation (NASDAQ:ABSI)’s ABS‑201 Shows Promise in Hair Loss Treatment, Analysts See Upside

Group 1 - Absci Corporation (NASDAQ:ABSI) is recognized as a promising multibagger penny stock, with analysts maintaining a Buy rating and setting price targets of $7 and $9, respectively, based on positive preclinical data for its drug ABS-201 [1][2] - The preclinical data for ABS-201 indicates its potential to stimulate hair growth in human scalp tissue samples, showcasing its effectiveness in treating androgenetic alopecia [2] - ABS-201 operates by targeting the prolactin receptor to promote hair growth while preserving stem cells, and it has shown the ability to extend the active growth phase of hair follicles [3] Group 2 - Current treatments for androgenetic alopecia do not address the reduced capacity of hair follicle stem cells, which is a key mechanism in this condition, highlighting the innovative approach of ABS-201 [4] - The drug is expected to significantly impact the market, as androgenetic alopecia affects approximately 80 million Americans, indicating a substantial potential customer base [5] - Absci Corporation is a clinical-stage biopharmaceutical company that utilizes a proprietary generative artificial intelligence platform for drug discovery and development [6]